These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 36987720)

  • 1. [Maintenance of efficacy and its predictors after discontinuation of eltrombopag in adults with primary immune thrombocytopenia].
    Sun HP; You JH; Chen QS; Wang J; Li JM
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):32-37. PubMed ID: 36987720
    [No Abstract]   [Full Text] [Related]  

  • 2. [Efficacy and safety of eltrombopag in the treatment of primary immune thrombocytopenia: real-world data from a single medical center].
    Dong XF; Li YL; Li NB; Lin WN; Wang T; Wang HQ; Li LJ; Qu W; Xing LM; Liu H; Wu YH; Wang GJ; Song J; Guan J; Wang XM; Shao ZH; Fu R
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):271-276. PubMed ID: 38716599
    [No Abstract]   [Full Text] [Related]  

  • 3. Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial.
    Cooper N; Ghanima W; Vianelli N; Valcárcel D; Yavaşoğlu İ; Melikyan A; Ruiz EY; Haenig J; Somenzi O; Lee J; Clark J; Zhang Y; Zaja F
    Am J Hematol; 2024 Jan; 99(1):57-67. PubMed ID: 38014779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term eltrombopag in children with chronic immune thrombocytopenia: A single-centre extended real-life observational study in China.
    Wang Z; Wang N; Juntao O; Ma J; Dong S; Meng J; Liu J; Chen Z; Cheng X; Wu R
    Br J Haematol; 2024 Mar; 204(3):1017-1023. PubMed ID: 38087811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term efficacy of eltrombopag in children with immune thrombocytopenia.
    Yang L; Sang BH; Yang CH; Xiao ZG; Fang CL; Lv Y; Li N; Yang Q; Chai SM; Tian X; Zhang XW; Huang TL
    Ann Hematol; 2024 Jun; ():. PubMed ID: 38916741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on eltrombopag concentration in pediatric immune thrombocytopenia: A single-center observational study in China.
    Dong S; Wang Z; Wang N; Ma J; Meng J; Sun Y; Cheng X; Wu R
    Pediatr Investig; 2024 Mar; 8(1):44-52. PubMed ID: 38516133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of clinical characteristics and treatment efficacy in two pediatric cases of
    Pang C; Wu X; Nikuze L; Wei H
    Platelets; 2023 Dec; 34(1):2262607. PubMed ID: 37852929
    [No Abstract]   [Full Text] [Related]  

  • 8. Expression and prognostic value of C-reactive protein in adult immune thrombocytopenia (ITP) patients.
    Zhang Y; Liu F; Liang X; Zhu J; Han L; Shi X; Cao J; Li Z; Chen W; Xu K; Cheng H
    Clin Exp Med; 2023 Dec; 23(8):4483-4491. PubMed ID: 36976377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of rectal cancer with immune thrombocytopenic purpura that achieved a complete response to continued chemotherapy with eltrombopag].
    Tanaka Y; Kuroda H; Honma K; Wakaki K
    Nihon Shokakibyo Gakkai Zasshi; 2023; 120(10):852-857. PubMed ID: 37821375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients.
    Hamed EM; Ibrahim ARN; Meabed MH; Khalaf AM; El Demerdash DM; Elgendy MO; Saeed H; Salem HF; Rabea H
    Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37765023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of eltrombopag in connective tissue disease patients with refractory immune thrombocytopenia: a retrospective study.
    Jiang X; Shu X; Ge Y
    Rheumatol Adv Pract; 2024; 8(2):rkae029. PubMed ID: 38495431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study.
    Jiménez-Bárcenas R; García-Donas-Gabaldón G; Campos-Álvarez RM; Fernández-Sánchez de Mora MC; Luis-Navarro J; Domínguez-Rodríguez JF; Nieto-Hernández MDM; Sánchez-Bazán I; Yera-Cobo M; Cardesa-Cabrera R; Jiménez-Gonzalo FJ; Ruiz-Cobo MA; Caparrós-Miranda I; Entrena-Ureña L; Fernández Jiménez D; Díaz-Canales D; Moreno-Carrasco G; Calderón-Cabrera C; Núñez-Vázquez RJ; Pedrote-Amador B; Mingot-Castellano ME;
    Br J Haematol; 2024 May; 204(5):1977-1985. PubMed ID: 38566598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of decitabine in patients with glucocorticoid-resistant primary immune thrombocytopenia: factors influencing treatment responses].
    Yang JH; Xue MJ; Zhang XL; Wei ZC; Shao LL; Shi Y; Hou M
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):567-571. PubMed ID: 37749037
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimizing the therapeutic window of sirolimus by monitoring blood concentration for the treatment of immune thrombocytopenia.
    Zhang Y; Quan Y; Wang D; Cassady K; Zou W; Xiong J; Yao H; Deng X; Wang P; Yang S; Zhang X; Feng Y
    Platelets; 2023 Dec; 34(1):2277831. PubMed ID: 38050853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Immune Thrombocytopenia and its Treatment Associated with Sarcopenia?
    Tuna MK; Erkek ET
    Niger J Clin Pract; 2024 Feb; 27(2):180-187. PubMed ID: 38409145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of successful treatment with eltrombopag for severe immune-related thrombocytopenia induced by atezolizumab:Case report.
    Harada S; Imakura T; Sato S; Nokihara H; Nishioka Y
    J Med Invest; 2023; 70(3.4):516-520. PubMed ID: 37940542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of vitamin D status in adult patients with newly diagnosed immune thrombocytopenia.
    Ciftciler R; Ciftciler AE; Yıldırımel C
    J Investig Med; 2024 Apr; 72(4):326-332. PubMed ID: 38373911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Care Team's Guide for Awareness on Risk Assessment of Eltrombopag Complicating Acute Kidney Injury in Relapsed Immune Thrombocytopenic Patients: A Case Report.
    Hamed EM; Meabed MH; Ibrahim ARN; Khalaf AM; El Demerdash DM; Elgendy MO; Saeed H; Mahmoud TM; Salem HF; Rabea H
    Medicina (Kaunas); 2023 Sep; 59(9):. PubMed ID: 37763764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcome and its Predictors in Children With Newly Diagnosed Immune Thrombocytopenia.
    Singaravadivelu P; Ramamoorthy JG; Delhi Kumar CG
    Indian Pediatr; 2024 Jun; 61(6):527-532. PubMed ID: 38554005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag plus diacerein vs. eltrombopag in patients with ITP: a multicenter, randomized, open-label, phase 2 trial.
    Sun L; Huang X; Wang J; Yuan C; Zhao H; Li D; Xu R; Wang Y; Qin P; Shi Y; Peng J; Hou M; Hou Y
    Blood; 2024 Jul; ():. PubMed ID: 38958479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.